# A Trial About the Measuring Instrument

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/a-trial-about-the-measuring-instrument

> SAMARA will be reported as showing semaglutide improves fatty liver disease. It was built to ask whether non-invasive tests can replace a biopsy, and the drug was the tool used to answer it.

## Key points

- The subject of the trial is the TEST, not the drug.
- Not one biopsy was done, so it cannot show the tests agree with tissue.
- Composite fibrosis score −0.28 vs −0.12 (P=0.002); ≥5% weight loss 64% vs 8.3%.
- N=55, about 27 per arm. The liver-fat result sits exactly on P=0.047.
- The score includes a fat measurement, so a fat-removing drug moves one of its own inputs.

SAMARA will be reported as a trial showing semaglutide improves fatty liver disease. That is not what it was built to ask. It was built to ask whether **blood tests and scans can replace a liver biopsy** for deciding who to treat and whether treatment is working. Semaglutide was the tool used to answer it.[1] The distinction changes what the result is good for.

## Why the question exists

Liver fibrosis has historically been graded by biopsy: a needle through the abdominal wall, a small piece of liver, a pathologist. It is the reference standard, but it is invasive, expensive, occasionally harmful, and impossible to repeat often enough to track whether a treatment is working.

Non-invasive tests were developed to avoid it. This trial used two: a liver stiffness measurement by ultrasound elastography, and a composite score built from stiffness, an enzyme level and a fat measurement. Both are already used in practice. What was missing was randomized evidence that they could *select* patients for treatment and then *register* whether that treatment did anything.

## What the trial did and found

Fifty-five people were randomized to weekly semaglutide 2.4 mg or placebo for 52 weeks. All met non-invasive criteria for at-risk fatty liver disease: a liver stiffness of at least 8 kPa and a composite score of at least 0.5. Average age was 48.8, average BMI 40.2, and one in five had diabetes.

*SAMARA at 52 weeks, semaglutide 2.4 mg against placebo.[1]*

| Outcome | Semaglutide | Placebo | P |
| --- | --- | --- | --- |
| Change in composite fibrosis score | −0.28 | −0.12 | 0.002 |
| Lost at least 5% of weight | 64% | 8.3% | <0.001 |
| Liver fat down by 30% or more on MRI | 60% | 17% | 0.047 |
| Liver enzymes, HbA1c, LDL | All improved further | — | <0.05 |

Gastrointestinal side effects were common in both arms and did not differ between them, which in a 55-person trial mostly tells you the trial was too small to separate them.

## What 'validated' can and cannot mean here

> **No one in this trial had a biopsy.** So it cannot tell you whether these tests agree with what a pathologist would see, and that agreement is what validating a replacement for biopsy would normally require. What it shows is that the scores *move* when an effective treatment is given, and move more than under placebo.

That is a useful thing to have shown, and a narrower one than it sounds. A test that responds to treatment is a candidate for monitoring treatment. Whether it responds *in proportion* to what is happening in the tissue, or to something adjacent (liver fat falling, weight falling, enzymes falling for reasons unconnected to fibrosis), is a separate question this design cannot reach.

The composite score used here includes a fat measurement as one of its inputs. A drug that removes liver fat will move that score partly by moving one of its own components. That does not make the result wrong; it means the score is not a pure fibrosis measure and should not be read as one.

## Fifty-five people

The sample size deserves its own section, because everything above rests on it. Fifty-five randomized, split two ways, is roughly twenty-seven per arm. At that size, each participant is worth close to four percentage points of any proportion in the table.

The liver fat result at P = 0.047 sits directly on the conventional threshold, which in a trial this size means a small number of people determined which side of it the finding landed. The composite score result at P = 0.002 is more robust, and the weight difference (64% against 8.3%) is large enough to be beyond argument.

> A trial can be well designed, honestly reported and too small to settle what it was designed to ask.

## What it means practically

- **For patients:** it supports using blood tests and scans rather than a biopsy to decide about treatment and follow it. That is a real improvement in what getting care feels like.
- **For the drug question:** it is consistent with semaglutide helping this condition, but it is far too small and too indirect to establish it. Larger trials with histology exist and are the place to look.
- **For anyone quoting it:** the endpoint was a test score, not liver tissue, and the trial's purpose was the test.

The broader problem of markers standing in for outcomes is in [a biomarker is not an outcome](https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome).

## Frequently asked questions

### Does semaglutide treat fatty liver disease?

This trial is consistent with that and cannot establish it. It randomized 55 people and measured a composite test score rather than liver tissue, because its purpose was to test whether non-invasive tests can be used instead of biopsy.

### What was the trial actually asking?

Whether blood tests and scans can identify people with at-risk fatty liver disease for treatment, and then register whether the treatment is working, so that patients can skip a liver biopsy. Semaglutide was the tool used to answer that.

### Were any biopsies done?

None. That means the trial cannot show these tests agree with what a pathologist would see, only that the scores move when an effective treatment is given.

### How reliable are the numbers?

The composite score result (P = 0.002) and the weight difference (64% vs 8.3%) are solid. The liver fat result sits exactly on the threshold at P = 0.047, and with roughly 27 people per arm, a small number of participants decided which side of it that landed.

### Can I avoid a liver biopsy now?

That is a decision for a hepatologist, and this trial adds support for the non-invasive route. It does not by itself change practice, at 55 participants and without histology to compare against.

## References

1. Ajmera V, Vuppalanchi R, Khalili M, et al. Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH—A Multicenter Randomised Placebo-Controlled Trial (SAMARA). Alimentary Pharmacology & Therapeutics. 2026. PMID: 41527269. https://pubmed.ncbi.nlm.nih.gov/41527269/

---

Cite as: GLP Watchdog, Nora Bissett, "A Trial About the Measuring Instrument", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/a-trial-about-the-measuring-instrument

Canonical HTML page: https://glpwatchdog.org/research/a-trial-about-the-measuring-instrument

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
